Blood transcriptomic signatures in children with tuberculosis in a treatment-shortening trial: Public, subject-level signature scores, RT-qPCR data, and metadata

Résumé fourni par la source

The SHINE trial demonstrated that 4 months of treatment was non-inferior to 6 months for children with non-severe tuberculosis drug-susceptible (DS-TB) as assessed on chest radiograph. However, the optimal duration likely varies between individuals. In the sub-study, an evaluation of blood transcriptomic signatures as non-sputum biomarkers of treatment response was carried out to explore their potential to inform individualised treatment duration in children.This sub-study included children (<16 years) with non-severe TB enrolled at a trial site in Cape Town, South Africa, with participants classified as having confirmed, unconfirmed, or unlikely TB. Here we provide the public, subject-level datasets containing key variables necessary to reconstruct findings from the SHINE sub-study aimed at evaluating the diagnostic performance of multiple parsimonious transcriptomic signatures. Gene expression of 20 transcriptomic signatures was measured in a sub-set of study participants from the Cape Town, South Africa study sites, one of the locations where the SHINE clinical trial was conducted. Gene expression data was generated from microfluidic RT-qPCR runs on mRNA derived from whole blood collected in PAXgene tubes. All results were verified before delta Ct values were calculated and used to compute signature scores.The public dataset for the sub-study is divided into (1) subject-level signature scores, and (2) subject-level TaqMan RT-qPCR primer-probe assay raw cycle threshold (CT) gene expression data from the Standard BioTools microfluidic gene expression integrated fluidic circuits, and (3) subject-level metadata.

Ce résumé expose les affirmations des auteurs. BNTIC ne l’interprète pas comme une validation indépendante des résultats.